Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

750 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.
Kong DS, Kim ST, Kim EH, Lim DH, Kim WS, Suh YL, Lee JI, Park K, Kim JH, Nam DH. Kong DS, et al. Among authors: nam dh. AJNR Am J Neuroradiol. 2011 Feb;32(2):382-7. doi: 10.3174/ajnr.A2286. Epub 2011 Jan 20. AJNR Am J Neuroradiol. 2011. PMID: 21252041 Free PMC article.
Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses.
Nickel AC, Picard D, Qin N, Wolter M, Kaulich K, Hewera M, Pauck D, Marquardt V, Torga G, Muhammad S, Zhang W, Schnell O, Steiger HJ, Hänggi D, Fritsche E, Her NG, Nam DH, Carro MS, Remke M, Reifenberger G, Kahlert UD. Nickel AC, et al. Among authors: nam dh. Biomed Pharmacother. 2021 Dec;144:112278. doi: 10.1016/j.biopha.2021.112278. Epub 2021 Oct 7. Biomed Pharmacother. 2021. PMID: 34628166 Free article.
Retraction Note: Tumour microenvironment programming by an RNA-RNA-binding protein complex creates a druggable vulnerability in IDH-wild-type glioblastoma.
Wu L, Zhao Z, Shin YJ, Yin Y, Raju A, Vaiyapuri TS, Idzham K, Son M, Lee Y, Sa JK, Chua JYH, Unal B, Zhai Y, Fan W, Huang L, Hu H, Gunaratne J, Nam DH, Jiang T, Tergaonkar V. Wu L, et al. Among authors: nam dh. Nat Cell Biol. 2025 Jan 16. doi: 10.1038/s41556-025-01613-0. Online ahead of print. Nat Cell Biol. 2025. PMID: 39820034 No abstract available.
A B7-H3-targeted CD28 bispecific antibody enhances the activity of anti-PD1 and CD3 T-cell engager immunotherapies.
Moore GL, Zeng VG, Diaz JE, Bonzon C, Avery KN, Rashid R, Qi J, Nam DH, Jacinto J, Dragovich MA, Kim YK, Balcazar KP, Bakhit CG, Eivazi A, Nguyen H, Muchhal US, Szymkowski DE, Desjarlais JR, Hedvat M. Moore GL, et al. Among authors: nam dh. Mol Cancer Ther. 2024 Sep 20. doi: 10.1158/1535-7163.MCT-24-0327. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39301613
750 results